Jacob Eriksen, PhD

Jacob Eriksen is the TPRML1 program lead and a principal scientist at Nine Square Therapeutics. He has been at Nine Square Therapeutics for four years and been part of the TRPML1 program from the early discovery phase. He has been leading the research efforts to show effects of the TRPML1 compounds in cellular models and more recently the in vivo biomarker discovery for the TRPML1 program. 

He has a PhD in Neuroscience from the University of Copenhagen during which he developed novel imaging methods for visualization of dopamine neurons. Subsequently he did a postdoc uncovering molecular mechanisms of excitatory synaptic transmission in the lab of Robert Edwards at the University of California San Francisco.